Joy Ho

1.2k total citations
14 papers, 323 citations indexed

About

Joy Ho is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Joy Ho has authored 14 papers receiving a total of 323 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 8 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in Joy Ho's work include Multiple Myeloma Research and Treatments (9 papers), Protein Degradation and Inhibitors (5 papers) and Peptidase Inhibition and Analysis (4 papers). Joy Ho is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Protein Degradation and Inhibitors (5 papers) and Peptidase Inhibition and Analysis (4 papers). Joy Ho collaborates with scholars based in Australia, New Zealand and France. Joy Ho's co-authors include John Gibson, Douglas Joshua, Christian Bryant, Ross Brown, Barbara Fazekas de St Groth, Antony Basten, Daniel Sze, Maria Raitakari, Alan G. Baxter and Peter Mollee and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Infectious Diseases.

In The Last Decade

Joy Ho

14 papers receiving 321 citations

Peers

Joy Ho

HEMAT

IMMUN

ONCOL

MB

EPIDE

Fabio Guolo Italy

Emily Heath Germany

Paola Minetto Italy

Shin‐ichi Fuchida Japan

Nimitha R. Mathew Sweden

Daiki Karigane Japan

Maria Regina Régis Silva Brazil

Darlene Monlish United States

Nobuyoshi Hanaoka Japan

Alexandra Cheerva United States

Fabio Guolo Italy

Joy Ho

112 ×0.7

HEMAT

91 ×0.7

IMMUN

127 ×1.1

ONCOL

78 ×0.7

MB

37 ×0.8

EPIDE

Citations per year, relative to Joy Ho Joy Ho (= 1×) peers Fabio Guolo

Countries citing papers authored by Joy Ho

Since Specialization

Citations

This map shows the geographic impact of Joy Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joy Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joy Ho more than expected).

Fields of papers citing papers by Joy Ho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joy Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joy Ho. The network helps show where Joy Ho may publish in the future.

Co-authorship network of co-authors of Joy Ho

This figure shows the co-authorship network connecting the top 25 collaborators of Joy Ho. A scholar is included among the top collaborators of Joy Ho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joy Ho. Joy Ho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

1.

Wellard, Cameron, et al.. (2023). Real‐world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry. Internal Medicine Journal. 54(5). 773–778. 1 indexed citations

2.

Bergin, Krystal, Cameron Wellard, Bradley Augustson, et al.. (2021). Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). Bone Marrow Transplantation. 56(10). 2533–2543. 9 indexed citations

3.

Joshua, Douglas, et al.. (2019). Biology and therapy of multiple myeloma. The Medical Journal of Australia. 210(8). 375–380. 89 indexed citations

4.

Dickinson, Michael, Leslie Popplewell, Arne Kolstad, et al.. (2019). ELARA: A phase II, single-arm, multicenter, open-label trial investigating the efficacy and safety of tisagenlecleucel in adult patients with refractory/relapsed follicular lymphoma (r/r FL).. Journal of Clinical Oncology. 37(15_suppl). TPS7573–TPS7573. 5 indexed citations

5.

Fox, Greg J., Thu Anh Nguyen, Hoa Binh Nguyen, et al.. (2018). Post-treatment Mortality Among Patients With Tuberculosis: A Prospective Cohort Study of 10 964 Patients in Vietnam. Clinical Infectious Diseases. 68(8). 1359–1366. 25 indexed citations

6.

Niesvizky, Rubén, Vânia Hungria, Joy Ho, et al.. (2017). Rates of peripheral neuropathy (PN) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM) treated with carfilzomib vs comparators in pivotal phase III trials.. Journal of Clinical Oncology. 35(15_suppl). 8041–8041. 3 indexed citations

7.

Bergin, Krystal, Elizabeth Moore, Zoe McQuilten, et al.. (2016). Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. BMC Medical Research Methodology. 16(1). 151–151. 22 indexed citations

8.

Quach, Hang, D. Joshua, Joy Ho, et al.. (2015). Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal. 45(3). 335–343. 11 indexed citations

9.

Quach, Hang, D. Joshua, Joy Ho, et al.. (2015). Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal. 45(1). 94–105. 11 indexed citations

10.

Yang, Shihong, Xin An, Ross Brown, et al.. (2005). Development of Retargeted CD38-Specific NK-92 Cell Line for Potential Anti-Myeloma Immunotherapy.. Blood. 106(11). 5104–5104. 5 indexed citations

11.

Sze, Daniel, Ross Brown, E. Yuen, et al.. (2003). Clonal Cytotoxic T Cells in Myeloma. Leukemia & lymphoma. 44(10). 1667–1674. 26 indexed citations

12.

Brown, Ross, Shihong Yang, John Gibson, et al.. (2003). Prediction of High Affinity Class I-restricted Multiple Myeloma Idiotype Peptide Epitopes. Leukemia & lymphoma. 44(9). 1557–1568. 7 indexed citations

13.

Brown, Ross, Shihong Yang, John Gibson, et al.. (2003). Prediction of High Affinity Class I-restricted Multiple Myeloma Idiotype Peptide Epitopes. Leukemia & lymphoma. 44(9). 1557–1568. 4 indexed citations

14.

Sze, Daniel, Ross Brown, Maria Raitakari, et al.. (2001). Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+CD28− compartment. Blood. 98(9). 2817–2827. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact